---
figid: PMC8870715__cells-11-00650-g001
figtitle: 'Recent Advances in Ovarian Cancer: Therapeutic Strategies, Potential Biomarkers,
  and Technological Improvements'
organisms:
- NA
organisms_ner:
- Danio rerio
- Homo sapiens
pmcid: PMC8870715
filename: cells-11-00650-g001.jpg
figlink: /pmc/articles/PMC8870715/figure/cells-11-00650-f001/
number: F1
caption: PI3K/Akt/mTOR signaling pathway. This pathway is upregulated in ovarian cancer
  by either (i) receptors of upstream growth factors and ligand stimulation, (ii)
  indirect activation via cross-talk with JAK/STAT signaling, or (iii) intrinsically
  via activation of amplified/mutated PI3K or amplification of Akt isoform, or deletion/inactivation
  in tumor-suppressor protein PTEN. Afuresertib, an Akt inhibitor, is safely used
  in platinum-resistant ovarian cancer. Most frequently studied mTOR inhibitors in
  completed OC phase II clinical trials are temsirolimus, ridaforolimus, and everolimus.
  Ruxolitinib, a JAK inhibitor, is already FDA approved for treatment of polycythemia
  vera.
papertitle: 'Recent Advances in Ovarian Cancer: Therapeutic Strategies, Potential
  Biomarkers, and Technological Improvements.'
reftext: Salima Akter, et al. Cells. 2022 Feb;11(4):650.
year: '2022'
doi: 10.3390/cells11040650
journal_title: Cells
journal_nlm_ta: Cells
publisher_name: MDPI
keywords: ovarian cancer | angiogenesis | technology advances | molecular insight
  | therapeutic strategies and targets
automl_pathway: 0.9326096
figid_alias: PMC8870715__F1
figtype: Figure
redirect_from: /figures/PMC8870715__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8870715__cells-11-00650-g001.html
  '@type': Dataset
  description: PI3K/Akt/mTOR signaling pathway. This pathway is upregulated in ovarian
    cancer by either (i) receptors of upstream growth factors and ligand stimulation,
    (ii) indirect activation via cross-talk with JAK/STAT signaling, or (iii) intrinsically
    via activation of amplified/mutated PI3K or amplification of Akt isoform, or deletion/inactivation
    in tumor-suppressor protein PTEN. Afuresertib, an Akt inhibitor, is safely used
    in platinum-resistant ovarian cancer. Most frequently studied mTOR inhibitors
    in completed OC phase II clinical trials are temsirolimus, ridaforolimus, and
    everolimus. Ruxolitinib, a JAK inhibitor, is already FDA approved for treatment
    of polycythemia vera.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - mdm2
  - tp53
  - bcl2a
  - birc5a
  - xiap
  - igfn1.2
  - ddx3xb
  - ptenb
  - pdk1
  - mtor
  - her2
  - her3
  - myca
  - ccnd1
  - vegfaa
  - egf
  - celsr1a
  - egfra
  - JAK1
  - JAK2
  - JAK3
  - TYK2
  - MDM2
  - TP53
  - TP63
  - TP73
  - NFKB1
  - RELA
  - RELB
  - REL
  - NFKB2
  - PDGFA
  - PDGFB
  - PDGFC
  - PDGFD
  - BCL2
  - XIAP
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - IGF1
  - ARHGEF7
  - CBFA2T2
  - PPP1R13B
  - PPP1R12C
  - CUX1
  - SART3
  - AKT1
  - AKT2
  - AKT3
  - ANGPT1
  - ANGPT2
  - ANGPT4
  - AREG
  - BDNF
  - CSF1
  - EFNA1
  - EFNA2
  - EFNA3
  - EFNA4
  - EFNA5
  - EGF
  - EREG
  - FGF1
  - FGF10
  - FGF16
  - FGF17
  - FGF18
  - FGF19
  - FGF2
  - FGF20
  - FGF21
  - FGF22
  - FGF23
  - FGF3
  - FGF4
  - FGF5
  - FGF6
  - FGF7
  - FGF8
  - FGF9
  - FLT3LG
  - HGF
  - IGF2
  - INS
  - KITLG
  - NGF
  - NTF3
  - NTF4
  - PGF
  - TGFA
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - PTEN
  - PDK1
  - PDPK1
  - RPS6KB1
  - RPS6KB2
  - EIF4EBP1
  - MTOR
  - ERBB2
  - ERBB3
  - MYC
  - CCND1
  - FGF11
  - FGF12
  - FGF13
  - FGF14
  - EGFR
---
